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ABSTRAK
Terapi antiplatelet sangat penting untuk pasien dengan penyakit jantung koroner yang menjalani prosedur 
drug-eluting stent (DES). Panduan klinis saat ini merekomendasikan dual antiplatelet (DAPT) dengan aspirin 
dan inhibitor P2Y12 selama minimal 12 bulan. Perpanjangan DAPT lebih dari 12 bulan dapat dipertimbangkan 
untuk mencegah very late stent trombosis. Beberapa faktor telah diketahui berkontribusi terhadap trombosis 
stent, termasuk diabetes dan usia lanjut, namun durasi optimal DAPT untuk pasien tersebut masih kontroversial. 
Kajian klinis ini membandingkan efektivitas terapi dual antiplatelet yang diperpanjang (>12 bulan) dibandingkan 
dengan durasi standar (12 bulan) dalam mengurangi kejadian infark miokard dan trombosis stent, terutama 
pada pasien diabetes berusia lanjut.
Pencarian literatur dilakukan dalam database PubMed dan Cochrane dengan menggunakan kata kunci 
“dual antiplatelet”, “durasi”, “diabetes melitus onset dewasa”, “usia lanjut”, dan “drug-eluting stent”. Jenis 
artikel berupa meta-analisis, uji klinis, atau uji klinis terandomisasi yang membandingkan dual antiplatelet 
diperpanjang dengan durasi standar. Keluaran klinis adalah infark miokard dan trombosis stent. Pencarian 
awal dilakukan secara spesifik untuk mencari penelitian pada populasi diabetes dan usia lanjut, namun lingkup 
pencarian diperluas menjadi pasien dewasa dengan/tanpa diabetes. Didapatkan 5 uji klinis dan 1 meta-analisis, 
yang menunjukkan penurunan risiko dalam kejadian trombosis stent dan infark miokard. Kajian klinis ini memiliki 
beberapa keterbatasan, antara lain potensi bias seleksi dan proporsi pasien diabetes serta usia lanjut yang 
terbatas dalam uji klinis. Kajian klinis ini menunjukkan bahwa lebih baik memberikan perpanjangan DAPT 
hanya untuk pasien dengan risiko iskemik tinggi dan risiko perdarahan rendah (tailored therapy).
Kata kunci: diabetes melitus, drug-eluting stent, dual antiplatelet diperpanjang, infark miokard, lanjut 
usia, trombosis stent.
ABSTRACT
Antiplatelet is an important drug for patients with coronary heart disease undergoing drug-eluting stent 
implantation. Current guidelines recommend dual antiplatelet with aspirin and a P2Y12 inhibitor for at least 12 
months. Continuation of DAPT beyond 12 months may be considered for preventing very late stent thrombosis. 
Several patient-related factors that contribute to stent thrombosis have been recognized, including diabetes and 
advanced age, but the optimal DAPT duration for these patients is still controversial. This article reviews the 
efficacy of extended (>12 months) compared to standard (12 months) DAPT for reducing myocardial infarction 
and stent thrombosis rates, especially in diabetic elderly patients.
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Literature screening was conducted at PubMed and Cochrane database using “dual antiplatelet”, 
“duration”, “adult-onset diabetes mellitus”, “elderly” and, “drug-eluting stent” as keywords. Article types 
were limited to meta-analysis, systematic review, randomized clinical trial, or clinical trial that compared 
the efficacy of extended to standard duration of DAPT. Clinical outcomes used were myocardial infarction 
and stent thrombosis. The initial search was done to find relevant studies specifically assessing diabetic and 
elderly patients, then widened to diabetic and non-diabetic patients of any age above eighteen years. A total 
of 5 clinical trials and 1 meta-analysis were reviewed, showing an overall risk reduction of stent thrombosis 
and myocardial infarction. This review has several limitations, such as its potential selection bias and under-
represented proportion of diabetic and elderly patients. High-risk subgroups like diabetes mellitus has a tendency 
of increased ischemic risk, while advanced age could have both increased ischemic risk and bleeding risk. This 
review suggests that it is better to reserve extended dual antiplatelet therapy for patients with high ischemic 
risk and low bleeding risk (tailored therapy).
Key words: adult-onset diabetes mellitus, drug-eluting stent, extended dual antiplatelet, elderly, myocardial 
infarction, stent thrombosis.
INTRODUCTION
Coronary  hear t  d i sease  i s  caused 
by atherosclerosis of coronary arteries. 
Revascularization of occluded coronary artery 
by percutaneous coronary intervention (PCI) 
could be indicated both in the setting of acute 
coronary syndrome (ACS) and non-ACS, such 
as refractory angina despite optimal medical 
treatment. A coronary stent, as foreign body in 
blood vessel, will induce platelet adhesion and 
aggregation, resulting in thrombus.1,2 Antiplatelet 
is an important therapy for inhibiting platelet 
aggregation and preventing stent thrombosis, 
especially in high-risk patients. The risk of 
stent thrombosis is increased dramatically in 
patients who prematurely discontinue antiplatelet 
therapy, and stent thrombosis is associated 
with a mortality rate of 20-45%.3 Currently, the 
American Heart Association recommends dual 
antiplatelet therapy (DAPT) with aspirin and 
P2Y12 inhibitor for at least 12 months, continued 
with aspirin monotherapy indefinitely for 
patients receiving drug-eluting stent (DES), both 
in ACS and non-ACS setting. Lately, it has been 
shown that DES has a higher incidence of very 
late stent thrombosis, which occurs more than 
12 months after stent implantation. Therefore, 
continuation of DAPT beyond 12 months may 
be considered in patients undergoing DES 
implantation. However, if the risk of morbidity 
from bleeding outweighs the anticipated benefit 
afforded by DAPT, earlier discontinuation of 
P2Y12 inhibitor therapy is reasonable.3
Several patient-related factors that contribute 
to stent thrombosis have been recognized, 
including diabetes and advanced age.3,4 
Diabetic patients are characterized by increased 
atherothrombotic risk, associated with their 
pro-inflammatory and prothrombotic status. 
Platelet function is regulated by insulin, and the 
adhesion or aggregation of platelets is enhanced 
in insulin-resistant patients. The up-regulation of 
the P2Y12 receptor signaling pathway has also 
been shown in type 2 diabetes. Platelet in diabetic 
patients appear to be in activated state even in 
the absence of vascular injury, and respond more 
frequently even to subthreshold stimuli. Insulin 
resistance also increases fibrinolysis suppression, 
and associated with the increased production of 
different coagulation factors promoting platelet 
adhesion to the vascular sub-endothelium.5 The 
complexity of platelet activation and subsequent 
higher risk of thrombosis in diabetic patients 
may become a reasonable consideration for 
prolonging DAPT beyond the recommended 
duration.
Coronary stent implantion is one of the most 
frequent hospital procedure done in elderly 
population, and the proportion of patients 
undergoing PCI who were 75 to 84 years of age 
has doubled, while those who were 85 years 
of age increased five fold.1,6 Elderly undergo 
physiological changes, such as increased arterial 
stiffness and endothelial dysfunction. In addition, 
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they usually present with multiple pathologies, 
such as hypertension, diabetes mellitus, and renal 
failure. Such conditions may lead to increased 
atherothrombotic risk, and it may be reasonable 
to prolong DAPT beyond the recommended 
duration. However, older patients are at 
higher risk of complications from antiplatelet 
therapies; it could make prolonging DAPT 
contraindicated despite the potential clinical 
benefit.7,8 In addition, elderly patients often 
have multipharmacological treatment with many 
potential drug-drug interactions.9 Therefore, 
any medication, including antiplatelet, should 
be scrutinized in order to determine whether it 
should be continued or not.
Several studies proved that dual antiplatelet 
therapy with aspirin and P2Y12 can decrease 
cardiovascular mortality in patients after coronary 
DES implantation. Even so, the optimal duration 
is still controversial. Therefore, clinicians need 
to know whether extended (>12 months) DAPT 
after DES implantation is: (1) indicated in all 
patients because the cardiovascular benefit 
outweighs the risk of bleeding; (2) considered in 
certain individual (tailored-therapy) with high-
risk profile (such as diabetic or elderly patient) 
based on patient’s cardiovascular risk factor and 
bleeding risk; (3) contraindicated in all patients 
because of significantly increased morbidity or 
mortality associated with bleeding risk.
CLINICAL QUESTION
In diabetic elderly patients, does extended 
dual antiplatelet (>12 months) after drug-eluting 
stent implantation reduce myocardial infarction 
and/or stent thrombosis rates better than standard 
(12 months) dual antiplatelet therapy? 
METHODS
The search strategy and study selection 
criteria were based on problem-intervention-
comparison-outcome (PICO) model to answer 
the clinical question, as described in Table 1. 
Since the cilinical question type is intervention, 
searching would be focused to find meta-
analysis, systematic review, or clinical trial to 
answer the clinical question.
Data Sources and Search Strategy
We screened Pubmed and Cochrane database 
on April 10–17, 2015 for data comparing 
extended duration and standard duration of dual 
antiplatelet therapy. Dual antiplatelet therapy 
was defined as aspirin plus a P2Y12 receptor 
inhibitor (clopidogrel, prasugrel, or ticagrelor). 
We used “dual antiplatelet”, “duration”, “adult-
onset diabetes mellitus”, “elderly” and, “drug-
eluting stent” as keywords. Filters were used 
to limit article types, which is “meta-analysis”, 
“systematic review”, “randomized clinical trial”, 
or “clinical trial”. No filter for date of publication 
was used, and the articles found were publicated 
between 2006 and 2015. The keywords and 
number of articles found in each search were 
listed in Table 2.
Selection Criteria
Articles included in this review were 
systematic review, meta-analysis, randomized 
clinical trial, or clinical trial comparing twelve and 
over twelve months dual antiplatelet therapy after 
drug-eluting stent implantation. Exclusion criteria 
for this review were: articles with observational 
design, dual antiplatelet duration of less than 
twelve months (clinical trial/meta-analysis/
systematic review) or duration timeframes not 
reported (meta-analysis or systematic review), 
animal studies, studies assessing endpoint other 
than stent thrombosis/ myocardial infarction, and 
studies assessing the effects of drug other than 
the combination of aspirin and a thienopyridine. 
Articles written in languages other than English 
or Indonesian were also excluded.
The initial search was done to find relevant 
studies specifically assessing diabetic and 
elderly patients. However, due to the scarcity of 
Table 1. PICO components
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such studies, the scope of search was widened 
gradually from diabetic and elderly patients, 
to diabetic and non-diabetic patients of any 
age above eighteen years old. Such steps were 
necessary to collect as many high-quality 
studies as possible. The literature screening, 
study selection, and reasons for exclusion were 
described in the PRISMA flowchart (Figure 1).
Selection Bias and Publication Bias
All relevant studies were included in this 
review, even studies with negative results. 
However, selection bias could happen because 
not all relevant studies have full-text availability. 
Several studies with no full-text availability 
were included in the meta-analysis we found, 
therefore they are indirectly included in this 
review. Ultimately, only one relevant clinical trial 
were not included due to no full-text availability. 
Eligible studies, which conformed to the 
inclusion and exclusion criteria, were assessed 
for their risk of bias. Publication bias was 
graded using the components of evidence-based 
medicine recommended by the British Medical 
Journal (BMJ), which consist of randomization, 
allocation concealment, blinding of participants, 
and other sources of bias. The characteristics of 
included studies, along with potential sources of 
bias were summarised in Table 3 and Table 4.
RESULTS
Studies and Patients
From the 95 initial studies, 86 studies did 
not meet the prespecified inclusion criteria. 
Table 2. Searching strategy in several database
Engines Search Terms Hits
Pubmed ((((((((dual antiplatelet) AND duration) AND drug eluting stent[MeSH Terms] AND aspirin[MeSH 
Terms]) AND thienopyridines[MeSH Terms])) AND elderly)) AND diabetes mellitus, adult 
onset[MeSH Terms]
0
Pubmed (((((((dual antiplatelet) AND duration) AND drug eluting stent[MeSH Terms] AND aspirin[MeSH 
Terms]) AND thienopyridines[MeSH Terms])) AND diabetes mellitus, adult onset[MeSH Terms]
0
Pubmed (((((dual antiplatelet) AND duration) AND drug eluting stent[MeSH Terms] AND aspirin[MeSH 
Terms]) AND thienopyridines[MeSH Terms])) AND elderly 
29
Pubmed (((dual antiplatelet) AND duration) AND drug eluting stent[MeSH Terms] AND aspirin[MeSH 
Terms]) AND thienopyridines[MeSH Terms]
49
Cochrane ‘dual antiplatelet AND “duration” AND “drug eluting stent” AND diabetes mellitus AND elderly 0
Cochrane ‘dual antiplatelet AND “duration” AND “drug eluting stent” AND diabetes mellitus 0
Cochrane ‘dual antiplatelet AND “duration” AND “drug eluting stent” AND elderly 0
Cochrane ‘dual antiplatelet AND “duration” AND “drug eluting stent” 46
A total of 5 clinical trials and 1 meta-analysis 
were finally included in the review (Figure 1). 
Clopidogrel and aspirin was the most frequent 
drug combination in dual antiplatelet therapy. 
Follow-up period varied from 18 to 48 months 
after stent implantation. Sample size varied 
between studies, from several hundreds to almost 
ten thousands. Each study had varying proportion 
of diabetic and elderly subjects. All studies had 
less than 50% diabetic subjects, and all studies 
had subjects with mean age over 60 years old. 
Only two studies analysed these high-risk 
subgroups separately (Table 3 and Table 4).10-15
Stent Thrombosis
In three randomized clinical trials, extended 
dual antiplatelet therapy have similar clinical 
benefit to twelve-month therapy. Extended 
dual antiplatelet therapy showed a reduction of 
roughly 50% in the rates of stent thrombosis for 
diabetic patients, and roughly 80% for elderly 
(>75 years old) patients. One clinical trial had 
no data for stent thrombosis, and another one 
reported a significantly different rates of stent 
thrombosis between the two groups, with a 
relatively small number needed to treat (Table 3). 
A meta-analysis showed a reduction of roughly 
70% in the odds of myocardial infarction and 
demonstrated statistically significant difference, 
but its number needed to treat (NNT) was 
relatively high (Table 4).
Myocardial Infarction
In two clinical trials, myocardial infarction 
rates were similar in twelve-month and extended 
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Figure 1. PRISMA flowchart
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Table 3. Characteristics of included clinical trials comparing 12 months versus extended (>12 months) dual antiplatelet 
therapy
Criteria
Twelve or 30 
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12 mo vs. 30 mo <12 mo vs >12mo 12 mo vs. 36 mo 12 mo vs. 36 mo 12 mo vs. 18 mo
Dual antiplatelet 
regimen 
aspirin 75 – 
162 mg + 
clopidogrel 75 
mg or prasugrel 
10 mg daily




mg + clopidogrel 
75 mg daily
aspirin 100-200 
mg + clopidogrel 
75 mg daily




stenting to group 
allocation 
12 months None (secondary 
data)
12 – 24 months 12 – 18 months 12 months
Non-adherence 

















30 months 48 months 36 months 36 months 18 months
Subjects (total) 9 961 14 925 2 701 5 045 336


















      Mean age 
(years old)




61.9 + 9.9 
(monotherapy)
62.3 + 10.1 
(monotherapy) 
64.7 + 7.5 
(monotherapy) 
61.8 + 10.2  
(dual therapy)
63.7+ 9.5 (dual 
therapy)
62.0 + 9.8 (dual 
therapy)
62.5 + 10.0 (dual 
therapy)
65.8 + 8.4 (dual 
therapy)
Subgroup analysis
  Diabetic: Stent 
thrombosis
HR 0.53  
(0.23 - 1.20)
None None None None
  Myocardial 
infarction
HR 0.73  
(0.51 – 1.05)
None None HR 0.63 (0.35 – 
1.12)
None
Elderly : (defined as >75 
years old)
(defined as >65 
years old)
Stent thrombosis HR 0.23  
(0.03 - 2.06)
None None None None
Myocardial 
infaction
HR 0.76  
(0.38 - 1.54)
None None HR 0.81 (0.51 – 
1.30)
None
Evidence quality Good Poor Fair Fair Poor
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dual antiplatelet therapy. In a randomized 
clinical trial, myocardial infarction rate differs 
significantly and the clinical benefit outweighs 
the bleeding risk, as shown by a number needed 
to treat of fifty patients or less. In DAPT trial, 
extended dual antiplatelet therapy showed 
a reduction of roughly 30% in the rates of 
myocardial infarction for diabetic patients, and 
roughly 30% for elderly (>75 years old) patients. 
In DES-LATE trial, extended dual antiplatelet 
therapy showed a reduction of roughly 40% in 
the rates of myocardial infarction for diabetic 
patients, and roughly 20% for elderly (>65 years 
old) patients. In another two trials, the clinical 
benefit is more pronounced, as shown by an even 
smaller number needed to treat; however, these 
trials have more potential bias than the other 
studies. A meta-analysis showed a reduction of 
roughly 50% in the odds of myocardial infarction 
with extended dual antiplatelet therapy and 
demonstrated statistically significant difference, 
but its number needed to treat was relatively high.
Table 4. Characteristics of included meta-analysis comparing 12 months versus extended (>12 months) dual antiplatelet 
therapy
Criteria
Optimal duration of dual antiplatelet therapy after percutaneous 
coronary intervention with drug eluting stents: meta-analysis of 
randomised controlled trials15
Is it a systematic review of high-quality studies 
which are relevant to your question?
Yes. All studies are randomized clinical trial comparing extended (>12 
mo) vs 12 mo dual therapy. Dual antiplatelet used are P2Y12 inhibitor 
and aspirin
Does it include a methods section that describes:
Finding and including all the relevant trials? Yes. Literature search were done in all major database, congress 
proceedings and unpublished research. All relevant randomized clinical 
trials were included
Assessing their individual validity? Yes
Were the results consistent from study to study? Yes. No significant heterogeneity for both outcomes (stent thrombosis 
and myocardial infarction), as indicated by p value > 0.1 and I2 < 40%




ARR = 0,66%  (0,41-0,91%)
CI 95%  = +/-0,25%  
NNT = 152 (109 – 244) pts





ARR = 1,34% (0,88 – 1,80%)
CI 95%  = +/-0,46%
NNT = 75 (55 – 114) pts
Odds Ratio 0,53 (0,42 – 0,66)
How precise are the results? The results can be interpreted with confidence. 
The confidence limits around the odds ratio demonstrated a statistical 
significance, favoring extended dual antiplatelet.
Evidence quality Good
*CER = Control Event Rate, EER = Experimental Event Rate, RRR = Relative Risk Reduction, ARR = Absolute Risk Reduction, 
CI = Confidence Interval, NNT = Number Needed to Treat
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DISCUSSION
There were variable results across the clinical 
trials, with some trials reporting clinical benefits 
in preventing stent thrombosis or myocardial 
infarction despite increased bleeding risk, while 
others reported no benefit. Three trials reported 
clinical benefit, one is an nonrandomized 
clinical trial with a relatively small sample size, 
and another one is also nonrandomized, with 
different dual antiplatelet duration within the 
trial. Accordingly, the good results might happen 
due to pure coincidence. Nonetheless, the clinical 
benefit might arise because a large proportion of 
patients in those trials had high ischemic risk, 
as indicated in the DAPT trial. The extended 
group also showed a greater risk reduction in 
myocardial infarction than stent thrombosis, 
which might demonstrate a protective effect of 
dual antiplatelet on preventing thrombosis in 
coronary vessels, beyond the stented area.10,11 
Two RCTs reported no clinical benefits from 
extended dual antiplatelet. However, these trials 
had inadequate statistical power and higher non-
adherence rates in dual therapy group, especially 
in Park, et al.12 In addition, the randomization 
occurred at a varying time-frame after stenting, 
mostly 18 months after stenting, so most subjects 
had stopped taking dual antiplatelet for six 
months.12,13 In those periods, the atherosclerotic 
process may had progressed; this could make 
dual antiplatelet, which primary function was 
for atherothrombotic prevention, less useful. 
Coupled with the high non-adherence rate, this 
could make the adverse events in dual therapy 
group slightly higher than monotherapy in 
Park, et al.12 Therefore, the results from these 
trials must be interpreted carefully. One meta-
analysis reported significant clinical benefit 
from extended dual antiplatelet. Different 
types of P2Y12 inhibitor and drug-eluting 
stents were used across and within trials. This 
situation reflected real-world clinical practice, 
where patients were treated with different 
antiplatelet and stent types, based on clinical 
settings and drug availability. Another problem 
was different extended antiplatelet duration and 
follow up period between trials, which might 
affect the clinical outcomes.14 Nonetheless, the 
meta-analysis showed little or no heterogeneity 
in the trials -suggesting that overall benefits 
of extended dual antiplatelet were robust and 
justified.15
Overall, the diabetic population is under-
represented in all clinical trials, moreover 
the elderly population. Elderly with multiple 
non-cardiovascular comorbidities, like many 
elderly patients in real-world clinical practice, 
were often excluded from trials, which further 
under-representing elderly population. The most 
representing clinical trial for these high-risk 
subgroups was Jia et al.14 However, it had many 
potential bias and inadequate statistical power. 
Therefore, none of the trials’ results could be 
extrapolated for diabetic or elderly subgroups.
The varying results from clinical trials might 
indicate that the certainty of whether extended 
therapy is better than twelve-month therapy, 
could not be generalized to all patients. This 
might be caused by a spectrum of risk factors, 
which played important roles in ischemic 
events, and resulted in a tendency of increasing 
clinical benefit (lower number needed to treat), 
in accordance with increasing proportion of 
high-risk patients. With evidence showing 
the tendency of greater clinical benefit from 
extended dual antiplatelet, the question was not 
whether to extend the dual therapy, but for whom 
the clinicians need to reserve the extended dual 
antiplatelet.
Diabetes
Coronary artery revascularization of diabetics 
continues to be a challenge: these patients suffer 
from a worse outcomes after PCI, compared with 
non-diabetics.16 This fact was also demonstrated 
in DAPT trial’s subgroup analysis, with a 
smaller risk reduction for both stent thrombosis 
and myocardial infarction in diabetic patients 
than their non-diabetic counterparts.10 Diabetic 
patients have been shown to have a poor response 
to clopidogrel in both the acute and chronic 
phases of therapy. Moreover, insulin-requiring 
diabetics have the strongest platelet reactivity 
despite dual antiplatelet therapy.5
While it has been known that diabetes 
mellitus is associated with prothrombotic 
state, the question of what is the most effective 
way to use antiplatelet therapy for this matter, 
remains un-answered. Currently, there is no 
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evidence that increasing aspirin dose would be 
useful. Increasing the loading or maintenance 
doses of clopidogrel may be an option. Several 
studies showed that increasing loading dose 
or maintenance dose would improve drug 
responsiveness and antiplatelet effects.5 The 
current low-dose aspirin/clopidogrel regimen has 
a slightly increased bleeding risk if used for an 
extended duration, as demonstrated consistently 
across all studies in this review. The bleeding 
was mainly mild or moderate, and rarely fatal. 
However, if the dose was increased, the bleeding 
risk could increase greatly. Further trials were 
needed to evaluate the safety profile of the high-
dose aspirin/clopidogrel regimen, as well as its 
clinical benefits, since most already existed trials 
measured laboratory outcomes, such as platelet 
activity, rather than clinical events.
Since most studies included in this review 
were performed under clopidogrel, further trials 
are needed to explore the effect of novel P2Y12 
inhibitor on diabetic patients. Several studies 
indicated that prasugrel, as well as ticagrelor, 
was more superior than clopidogrel in preventing 
recurrent ischemic events for post-ACS diabetic 
patients. Since dual antiplatelet with clopidogrel 
was indicated to have deleterious effect on 
advanced diabetic nephropathy, using a novel 
P2Y12 inhibitor or other antiplatelet, such as 
cilostazol, to replace clopidogrel might be an 
option for such patients.16,17 Another option was 
adding a third antiplatelet, such as cilostazol; 
preliminary studies showed a more pronounced 
clinical benefit of triple antiplatelet compared 
to dual antiplatelet in diabetic patients.18 Finally, 
the drug-eluting stent itself might also play 
a role in stent thrombosis, both in diabetic 
and general population, but no studies to date 
has evaluated the effects of extended dual 
antiplatelet therapy on different drug-eluting 
stent types.19-22 Additionally, in real clinical 
practice, a diabetic patient often has several 
comorbidities or complications, which might 
increase the ischemic risk. Therefore, further 
risk stratification are needed to evaluate each 
diabetic subgroups, such as diabetics receiving 
DES for ACS indications, insulin-requiring 
diabetics, diabetics without complications, with 
left ventricle systolic dysfunction, or with renal 
failure.
Elderly
In the subgroup analysis, the incidence of 
major/moderate bleeding in elderly patients 
was surprisingly lower than non-elderly.9 This 
might be caused by pure coincidence, as a 
result of much smaller proportion of elderly 
patients compared to non-elderly. Moreover, 
the elderly included in the trial, by design, most 
likely had a relatively low risk of bleeding, 
who experienced no major bleeding during 
twelve-month dual antiplatelet and tolerated the 
therapy well. Meanwhile, in real-world clinical 
practice, elderly patients could present with 
comorbidities which can increase the bleeding 
risk, such as peptic ulcer or esophageal varices. 
Results from DAPT trial also showed increasing 
cancer-related bleeding in extended dual-therapy 
group, most likely caused by undiagnosed cancer 
before enrollment.9 Several comorbidities could 
require drugs that increase bleeding risk, such as 
anticoagulants, glucocorticosteroid, or NSAID.23 
Certain drugs has also been shown to have 
impact on antiplatelet drugs, such as proton-
pump inhibitor (PPI), especially omeprazole 
and esomeprazole.4 Therefore, it is necessary 
to do a comprehensive and holistic assessment 
for elderly patients, especially to screen for 
comorbidities which can increase ischemic or 
bleeding risk. It is also important to use rational 
prescribing to avoid potential drug interactions.
Several studies indicated an increasing 
clinical benefit of extended dual antiplatelet for 
patients with high ischemic risk. However, there 
is no good evidence that could show the optimal 
duration of dual antiplatelet for elderly patients, 
who often had risk factors for both ischemic 
and bleeding events. Therefore, further trials 
are needed to evaluate the efficacy of extended 
dual antiplatelet therapy on elderly populations, 
especially in elderly with multiple pathologies.
Implications for Clinical Practice
Studies included in this review showed a 
tendency of greater clinical benefit from extended 
dual antiplatelet. However, as the incidence of 
very late stent thrombosis in general population 
is very small, the number needed to treat becomes 
very large, far over fifty patients. It indicates that 
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the use of extended dual antiplatelet therapy for 
every post-DES patients is ineffective, exposing 
patients to unnecessary bleeding risk, and clearly 
not cost-effective. This is especially important 
in Asian population, which has a relatively low 
incidence of very late stent thrombosis.24
Overall, this review suggests that the standard 
twelve-month dual antiplatelet therapy is not 
necessarily the optimal care. Longer duration 
should be carefully considered, weighing the 
patient’s bleeding and ischemic risk profile. Due 
to the uncertainty on increased bleeding risk, an 
extended dual antiplatelet regimen may better 
reserved to patients at high ischemic risk and low 
bleeding risk. Further trials with adequate power 
are needed to test the clinical efficacy of such 
tailored dual antiplatelet. This review can-not 
be used as a guide for tailoring dual antiplatelet 
therapies for a specific patient. However, it can 
provide a little insight on which patient is more 
likely need an extended dual antiplatelet therapy.
Limitations
This article has several limitations. First, 
its potential selection bias due to full-text 
unavailability. However, it is minimized by 
including meta-analysis, which analyzed the 
trials unavailable to the authors. Second, the trials 
have an under-represented proportion of diabetic 
and elderly patients, therefore results can-not 
be extrapolated in these high-risk subgroups. 
Third, this review only analyzed patient-related 
factors, not attending to other factors which may 
contribute to clinical outcomes, such as stent-
related factors and different dual antiplatelet 
regimens. Lastly, this review did not compare the 
efficacy between different extended antiplatelet 
duration.
CONCLUSION
It is not beneficial to extend dual antiplatelet 
therapy for every patients receiving drug-
eluting stents. Overall, the extended dual 
antiplatelet therapy showed a risk reduction of 
stent thrombosis and myocardial infarction, at 
the price of increased bleeding risk. High-risk 
subgroups like diabetes mellitus has a tendency 
of increased ischemic risk, while advanced 
age could have both increased ischemic risk 
and bleeding risk. This review suggests that it 
is better to reserve extended dual antiplatelet 
therapy for patients with high ischemic risk and 
low bleeding risk (tailored therapy).
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